Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Intratumoral Injection of Clostridium novyi -NT Spores in Patients with Treatment-refractory Advanced Solid Tumors
Jankú, Filip , Zhang, Halle Huihong, Pezeshki, Abdulmohammad, Goel, Sanjay , Helgason, Thorunn, Masters, Tyler, Hong, David S. , Piha‐Paul, Sarina A. , Karp, Daniel D. , Klang, Mark , Sakamuri, Divya, Raina, Anjali, Torrisi, Jean , Solomon, Stephen B. , Weissfeld, Alice S., Trevino, Ernest, DeCrescenzo, Gary, Collins, Amanda, Miller, Maria, Salstrom, Jennifer L., Korn, Ronald L. , Zhang, Linping , Saha, Saurabh , Leontovich, Alexey A. , Tung, David, Kreider, Brent L. , Varterasian, Mary , Khazaie, Khashayarsha , Gounder, Mrinal M. , Hong, David S , Klang, Mark , Kreider, Brent , Goel, Sanjay , Piha-Paul, Sarina A , Pezeshki, Abdulmohammad , Murthy, Ravi , Wang‐Gillam, Andrea , Shepard, Dale R. , Huang, Steven Y. , Collins, Amanda, Tung, David

Mayo Clinic

Clinical Cancer Research | October 12, 2020 | Volume: 27 | Issue: 1 | Pages: 96-106

10.1158/1078-0432.ccr-20-2065 | PMID 33046513 Get It

Abstract Purpose: Intratumorally injected Clostridium novyi-NT (nontoxic; lacking the alpha toxin), an attenuated strain of C. novyi, replicates within hypoxic tumor regions resulting in tumor-confined cell lysis and inflammatory response in animals, which warrants clinical investigation. Patients and Methods: This first-in-human study (NCT01924689) enrolled patients with injectable, treatment-refractory solid tumors to receive a single intratumoral injection of C. novyi-NT across 6 dose cohorts (1 × 104 to 3 × 106 spores, 3+3 dose-escalation design) to determine dose-limiting toxicities (DLT), and the maximum tolerated dose. Results: Among 24 patients, a single intratumoral injection of C. novyi-NT led to bacterial spores germination and the resultant lysis of injected tumor masses in 10 patients (42%) across all doses. The cohort 5 dose (1 × 106 spores) was defined as the maximum tolerated dose; DLTs were grade 4 sepsis (n = 2) and grade 4 gas gangrene (n = 1), all occurring in three patients with injected tumors >8 cm. Other treatment-related grade ≥3 toxicities included pathologic fracture (n = 1), limb abscess (n = 1), soft-tissue infection (n = 1), respiratory insufficiency (n = 1), and rash (n = 1), which occurred across four patients. Of 22 evaluable patients, nine (41%) had a decrease in size of the injected tumor and 19 (86%) had stable disease as the best overall response in injected and noninjected lesions combined. C. novyi-NT injection elicited a transient systemic cytokine response and enhanced systemic tumor-specific T-cell responses. Conclusions: Single intratumoral injection of C. novyi-NT is feasible. Toxicities can be significant but manageable. Signals of antitumor activity and the host immune response support additional studies of C. novyi-NT in humans.
RDH10 and ATRA sensitize triple-negative breast cancer to taxane-based chemotherapy through regulation of PIN1
Grainger, Jordan, Zhang, Lingxin , Yu, Jia , Vedell, Peter T. , Wang, Liewei , Thompson, Kevin, Kalari, Krishna R. , Suman, Vera J. , Boughey, Judy C. , Goetz, Matthew P.

Mayo Clinic

No container title available | October 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-86064/v1 Get It

Abstract Background: With few targeted therapies available for triple-negative breast cancer (TNBC), there is a critical need to identify biomarkers that can predict chemotherapy-response. Copy number amplifications (CNAmps) have been implicated in tumorigenesis, progression, and treatment response. Previously, we performed a prospective neoadjuvant chemotherapy study (BEAUTY) and identified a 5 Mb CNAmp in TNBC patients associated with pathological complete response rates to taxane- and anthracycline-based chemotherapy. Here we further interrogated this amplicon and its role in chemotherapy response. Methods: Using siRNA screening of genes identified in the 5 Mb CNAmp, followed by cytotoxicity assays, we identified RDH10 significantly associated with chemo-sensitivity in TNBC cell lines. Functional studies were performed using RDH10 knockdown or overexpression followed by cytotoxicity, cell proliferation, luciferase reporter assays, HPLC or western blot.Results: RDH10 is a rate-limiting step involved in the synthesis of all-trans retinoic acid (ATRA) - the active metabolite of retinoid metabolism that is frequently aberrant in cancer. Previous studies demonstrated ATRA to be a potent inhibitor of PIN1, a key regulator of several oncogenic signaling pathways often amplified in TNBC. We discovered that genetic manipulation of RDH10 affected ATRA intracellular concentrations, contributing to PIN1 degradation and taxane-response. Furthermore, co-treatment of TNBC cells with ATRA significantly increased taxane-sensitivity.Conclusion: RDH10 amplification increases endogenous levels of ATRA and degrades PIN1 in TNBC. ATRA-mediated degradation of PIN1 sensitizes TNBC to chemotherapy, suggesting that RDH10 may be a novel biomarker of taxane response and the addition of ATRA to standard chemotherapy may improve chemo-sensitivity.
Myeloid/Lymphoid Neoplasms Associated With Eosinophilia and Rearrangements of PDGFRA , PDGFRB , or FGFR1 or With
Kelemen, Katalin, King, Rebecca L. , Reichard, Kaaren K. , Craig, Fiona E. , Horny, Hans-Peter, Wang, Sa A. , Rimsza, Lisa, Pozdnyakova, Olga , Orazi, Attilio , Quintanilla‐Martínez, Leticia , Rimsza, Lisa M. , George, Tracy I.

Mayo Clinic

American Journal of Clinical Pathology | October 4, 2020 | Volume: 155 | Issue: 2 | Pages: 160-178

10.1093/ajcp/aqaa208 | PMID 33367495 Get It

Abstract Objectives To summarize cases submitted to the 2019 Society for Hematopathology/European Association for Haematopathology Workshop under the category of myeloid/lymphoid neoplasms with eosinophilia and PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2 rearrangements, focusing on recent updates and relevant practice findings. Methods The cases were summarized according to their respective gene rearrangement to illustrate the spectrum of clinical, laboratory, and histopathology manifestations and to explore the appropriate molecular genetic tests. Results Disease presentations were heterogeneous, including myeloproliferative neoplasms (MPNs), myelodysplastic syndromes (MDSs), MDS/MPN, acute myeloid leukemia, acute B- or T-lymphoblastic lymphoma/acute lymphoblastic lymphoma (ALL/LBL), or mixed-lineage neoplasms. Frequent extramedullary involvement occurred. Eosinophilia was common but not invariably present. With the advancement of RNA sequencing, cryptic rearrangements were recognized in genes other than PDGFRA. Additional somatic mutations were more frequent in the FGFR1-rearranged cases. Cases with B-ALL presentations differed from Philadelphia-like B-ALL by the presence of an underlying MPN. Cases with FLT3 and ABL1 rearrangements could be potential candidates for future inclusion in this category. Conclusions Accurate diagnosis and classification of this category of myeloid/lymphoid neoplasms has important therapeutic implications. With the large number of submitted cases, we expand our understanding of these rare neoplasms and improve our ability to diagnose these genetically defined disorders.
Comparison of echocardiographic parameters with cardiac magnetic resonance imaging in the assessment of right ventricular function
Agasthi, Pradyumna , Siegel, Robert J. , Pujari, Sai Harika , Mookadam, Farouk , Venepally, Nithin R. , Wang, Panwen , Marcotte, François , Semkiv, Oksana I., Fath, Ayman R. , Jokerst, Clinton, Arsanjani, Reza , Ashraf, Hasan , Allam, Mohamed N A, Arsanjani, Reza , Chao, Chieh‐Ju , Mookadam, Farouk , Ashraf, Hasan, Brown, Lisa, Allam, Mohamed

Mayo Clinic

Echocardiography | October 4, 2020 | Volume: 37 | Issue: 11 | Pages: 1792-1802

10.1111/echo.14877 | PMID 33012034 Get It

AbstractIntroductionThe right ventricle (RV) strain measured by speckle tracking (RVS) is an echocardiographic parameter used to assess RV function. We compared RVS to RV fractional area change (FAC%), tricuspid annular plane systolic excursion (TAPSE) and Doppler tissue imaging‐derived peak systolic velocity (Sʹ) in the assessment of right ventricular (RV) systolic function measured using cardiac magnetic resonance imaging (MRI).MethodsWe enrolled consecutive patients who underwent cardiac MRI between Jan 2012 and Dec 2017 and a transthoracic echocardiogram (TTE) within 1 month of the MRI with no interval event. Baseline clinical characteristics and MRI parameters were extracted from chart review. Echocardiographic parameters were measured prospectively. TTE parameters including RVS, TAPSE, Sʹ, and FAC% were tested for accuracy to identify impaired RV EF (EF < 45% & <30%) using receiver operator curves.ResultsThe study cohort included 500 patients with mean age 55 years ± 18 and peak tricuspid regurgitation velocity 2.7 ± 1.4 m/s. The area under ROC for RVS was 0.69 (95% CI 0.63–0.75) and 0.78 (95% CI 0.70–0.88) to predict RVEF < 45% & RVEF < 30%, respectively. The RV FAC% had second highest accuracy of predicting RVEF among all the TTE parameters tested in study.ConclusionRight ventricular strain is the most accurate echocardiographic method to detect impaired right ventricular systolic function when using MRI as the gold standard.
Reactive Eosinophil Proliferations in Tissue and the Lymphocytic Variant of Hypereosinophilic Syndrome
King, Rebecca L. , Tan, Brent , Craig, Fiona E. , Horny, Hans-Peter, Kelemen, Katalin, Reichard, Kaaren K. , Wang, Sa A. , Zamò, Alberto , Zamò, Alberto , George, Tracy I. , Orazi, Attilio , Rimsza, Lisa M. , Quintanilla‐Martínez, Leticia

Mayo Clinic

American Journal of Clinical Pathology | October 3, 2020 | Volume: 155 | Issue: 2 | Pages: 211-238

10.1093/ajcp/aqaa227 | PMID 33367482 Get It

Abstract Objectives The 2019 Society for Hematopathology and European Association for Haematopathology Workshop reviewed the spectrum of neoplastic, nonneoplastic, and borderline entities associated with reactive eosinophilia in tissue. Methods The workshop panel reviewed 46 cases covered in 2 workshop sessions. Results The 46 cases were presented with their consensus diagnoses during the workshop. Reactive eosinophilia in lymph nodes and other tissues may be accompanied by or be distinct from peripheral blood eosinophilia. Reactive etiologies included inflammatory disorders such as Kimura disease and IgG4-related disease, which may show overlapping pathologic features and reactions to infectious agents and hypersensitivity (covered in a separate review). Hodgkin, T-cell, and B-cell lymphomas and histiocytic neoplasms can result in reactive eosinophilia. The spectrum of these diseases is discussed and illustrated through representative cases. Conclusions Reactive eosinophilia in lymph nodes and tissues may be related to both nonneoplastic and neoplastic lymphoid proliferations and histiocytic and nonhematolymphoid processes. Understanding the differential diagnosis of reactive eosinophilia and the potential for overlapping clinical and pathologic findings is critical in reaching the correct diagnosis so that patients can be treated appropriately.
Multifocal Cryoballoon Ablation for Eradication of Barrett's Esophagus-Related Neoplasia: A Prospective Multicenter Clinical Trial
Rosenblum, Michael , Dumot, John A. , Chak, Amitabh , Iyer, Prasad G. , Khara, Harshit S. , Corbett, F Scott , McKinley, Matthew , Shin, Eun Ji , Waxman, Irving , Infantolino, Anthony, Tofani, Christina , Samarasena, Jason , Chang, Kenneth J. , Wang, Bingkai , Goldblum, John R. , Voltaggio, Lysandra , Lightdale, Charles J. , Shaheen, Nicholas J. , Iyer, Prasad, Canto, Marcia Irene , Trindade, Arvind J. , Abrams, Julian A , Diehl, David L. , Montgomery, Elizabeth Anne

Mayo Clinic

American Journal of Gastroenterology | October 2, 2020 | Volume: 115 | Issue: 11 | Pages: 1879-1890

10.14309/ajg.0000000000000822 | PMID 33156107 Get It

INTRODUCTION: Ablation of Barrett's esophagus (BE) is the preferred approach for the treatment of neoplasia without visible lesions. Limited data on cryoballoon ablation (CBA) suggest its potential clinical utility. We evaluated the safety and efficacy of CBA in a multicenter study of patients with neoplastic BE. METHODS: In a prospective clinical trial, 11 academic and community centers recruited consecutive patients with BE of 1–6 cm length and low-grade dysplasia, high-grade dysplasia (HGD), or intramucosal adenocarcinoma (ImCA) confirmed by central pathology. Patients with symptomatic pre-existing strictures or visible BE lesions had dilation or endoscopic mucosal resection (EMR), respectively, before enrollment. A nitrous oxide cryoballoon focal ablation system was used to treat all visible columnar mucosa in up to 5 sessions. Study end points included complete eradication of all dysplasia (CE-D) and intestinal metaplasia (CE-IM) at 1 year. RESULTS: One hundred twenty patients with BE with ImCA (20%), HGD (56%), or low-grade dysplasia (23%) were enrolled. In the intention-to-treat analysis, the CE-D and CE-IM rates were 76% and 72%, respectively. In the per-protocol analysis (94 patients), the CE-D and CE-IM rates were 97% and 91%, respectively. Postablation pain was mild and short lived. Fifteen subjects (12.5%) developed strictures requiring dilation. One patient (0.8%) with HGD progressed to ImCA, which was successfully treated with EMR. Another patient (0.8%) developed gastrointestinal bleeding associated with clopidogrel use. One patient (0.8%) had buried BE with HGD in 1 biopsy, not confirmed by subsequent EMR. DISCUSSION: In patients with neoplastic BE, CBA was safe and effective. Head-to-head comparisons between CBA and other ablation modalities are warranted (clinicaltrials.gov registration NCT02514525).
Cerebral venous sinus thrombosis associated with spontaneous heparin-induced thrombocytopenia syndrome after total knee arthroplasty
Hwang, Steven R. , Wang, Yuxiang , Weil, Erika L. , Padmanabhan, Anand , Warkentin, Theodore E. , Pruthi, Rajiv K. , Hwang, Steven R

Mayo Clinic

Platelets | October 1, 2020 | Volume: 32 | Issue: 7 | Pages: 936-940

10.1080/09537104.2020.1828574 | PMID 33000657 Get It

Use of Palpation Imaging in Diagnosis of Breast Diseases: A Way to Improve the Detection Rate
Ding, Yihan , Sun, Chenyu , Zhou, Qin , Cheng, Ce, Yan, Cunye, Wang, Benzhong , Sun, Chenyu

Mayo Clinic

Medical Science Monitor | October 1, 2020 | Volume: 26 | Issue: No issue available | Pages: No page available

10.12659/msm.927553 | PMID 33247894 Get It

Comparative Effectiveness of Generic vs Brand-Name Levothyroxine in Achieving Normal Thyrotropin Levels
Brito, Juan P. , Sangaralingham, Lindsey R. , Graham, David J. , Wang, Zhong , Wu, Yute, Smallridge, Robert C., Bernet, Victor , Shah, Nilay D. , Sangaralingham, Lindsey, Yao, Xiaoxi , Brito, Juan P , Ross, Joseph S. , Dutcher, Sarah K. , Lipska, Kasia J.

Mayo Clinic

JAMA Network Open | September 30, 2020 | Volume: 3 | Issue: 9 | Pages: e2017645

10.1001/jamanetworkopen.2020.17645 | PMID 32997127 Get It

Renal-function change after transjugular intra-hepatic portosystemic shunt placement and its relationship with survival: a single-center experience
Lang, Min , Lang, Angela L. , Tsui, Brian , Wang, Weiping , Shen, Bo , Kapoor, Baljendra , Erly, Brian

Mayo Clinic

Gastroenterology Report | September 29, 2020 | Volume: 9 | Issue: 4 | Pages: 306-312

10.1093/gastro/goaa081 | PMID 34567562 Get It

Abstract Background The effect of transjugular intra-hepatic portosystemic shunt (TIPS) placement on renal function and the correlation of post-TIPS Cr with mortality remain unclear. This study aimed to assess the effect of TIPS placement on renal function and to examine the relationship between post-TIPS Cr and mortality risk. Methods A total of 593 patients who underwent de novo TIPS placement between 2004 and 2017 at a single institution were included in the study. The pre-TIPS Cr level (T0; within 7 days before TIPS placement) and post-TIPS Cr levels, at 1–2 days (T1), 5–12 days (T2), and 15–40 days (T3), were collected. Predictors of Cr change after TIPS placement and the 1-year mortality rate were analysed using multivariable linear-regression and Cox proportional-hazards models, respectively. Results Overall, 21.4% of patients (n = 127) had elevated baseline Cr (≥1.5 mg/dL; mean, 2.51 ± 1.49 mg/dL) and 78.6% (n = 466) had normal baseline Cr (&lt;1.5 mg/dL; mean, 0.92 ± 0.26 mg/dL). Patients with elevated pre-TIPS Cr demonstrated a decrease in post-TIPS Cr (difference, −0.60 mg/dL), whereas patients with normal baseline Cr exhibited no change (difference, &lt;0.01 mg/dL). The 30-day, 90-day, and 1-year mortality rates were 13%, 20%, and 32%, respectively. Variceal bleeding as a TIPS-placement indication (hazard ratio = 1.731; P = 0.036), higher T0 Cr (hazard ratio = 1.834; P = 0.012), and higher T3 Cr (hazard ratio = 3.524; P &lt; 0.001) were associated with higher 1-year mortality risk. Conclusion TIPS placement improved renal function in patients with baseline renal dysfunction and the post-TIPS Cr level was a strong predictor of 1-year mortality risk.